Mr. Dennis Hancock reports

MOUNTAIN VALLEY MD EXECUTES SOLUVEC 1% LICENSE AGREEMENT, EXPANDS PATENT PROTECTION

Mountain Valley MD Holdings Inc.'s Mountain Valley MD Inc. has entered into a licence agreement with a privately held Ontario corporation (the licensee) for its Soluvec 1 per cent animal husbandry applications for the territory of Bangladesh.

As previously disclosed, the company has applied its Quicksol solubilization technology to the drug ivermectin to create its Soluvec 1 per cent product formulation, which was designed to provide a safer and more effective solution that can be administered broadly across the animal husbandry and aquatic species marketplace. Mountain Valley has worked closely with the licensee and its partners inside Bangladesh on the previously disclosed animal pharmacokinetic trials that were conducted under the supervision of Bangladesh's Ministry of Fisheries & Livestock for the injectable Soluvec 1 per cent solubilized Ivermectin technology, and Soluvec 1 per cent-coated standard fish feed across farmed fish species. The agreement provides the licensee with the exclusive rights, within Bangladesh, to work through its partners inside the territory to co-ordinate Soluvec 1 per cent manufacturing and distribution of related Soluvec 1 per cent products, both in injectable and food coating applications. In consideration, the licensee will pay Mountain Valley a royalty percentage against net sales in the region.

"We have come a long way from the first meeting where we asked ourselves how we could improve animal husbandry health outcomes to directly impact the GDP [gross domestic product] of key third world countries," stated Dennis Hancock, president and chief executive officer of Mountain Valley. "Moving forward to commercialize inside Bangladesh is exciting validation of our progress, while laying the foundation for expansion plans for other key markets."

Expanded country patent protection

Quicksol is the company's patented solubilization technology, which has been developed to provide solubilized drug delivery options across the macrocyclic lactone class of anti-parasitic drugs.

To safeguard its intellectual property and the company's licensing royalty model, Mountain Valley has initially filed for Quicksol patent protection in key markets it has deemed strategically important at this time for expansion outside of Bangladesh. Throughout the month of April, 2023, Mountain Valley has filed for Soluvec protection in 12 additional markets outside of the United States, including Canada, China, India, Mexico, Sri Lanka, Thailand, the Philippines, Malaysia, Brazil, Peru, Argentina and Chile.

Soluvec 1 per cent pharmacokinetic trials

Related to the agreement and necessary government approvals, the pharmacokinetic trials conducted inside Bangladesh across husbandry and aquatic species categories have been completed by a third party contract research organization (CRO), and Mountain Valley believes the results of these trials will positively support the value proposition necessary to secure requisite government approvals to commercialize inside Bangladesh in the 2023 calendar year.

The pharmacokinetic trials for Soluvec 1 per cent involved administering the drug through intramuscular (IM) and subcutaneous (SC) injection, as well as orally with commercially available branded ivermectin. The trials also included comparative studies of growth performance, toxicity and blood hematological observation for Soluvec 1 per cent coated standard fish feed among various farmed fish species.

The trials demonstrated that Soluvec 1 per cent has a solubility approximately 2,500 times greater than free ivermectin. Additionally, IM and SC Soluvec 1 per cent administration increased ivermectin drug exposure, peak levels and extended the duration of ivermectin exposure in husbandry animals when compared with commercially available ivermectin in SC, IM and oral forms.

Farmed fish trials were conducted on Indian catfish, pangas, common carp, tilapia and rui (ruho) fish species. One group received Soluvec 1 per cent coated standard fish feed, while the control group was given non-Soluvec 1 per cent standard fish feed. The results showed an increase in average daily growth and a reduction in mortality, leading to an overall net average increase in net production of 145 per cent. The feed conversion ratio also improved by an average of 16 per cent for all fish species treated with Soluvec 1 per cent-coated fish feed compared with those receiving non-Soluvec 1 per cent-coated fish feed, indicating that the former group required less feed to produce higher units of biomass.

"Bangladesh has the third largest farmed fish output in the world, only trailing China and India," continued Mr. Hancock. "We view these positive results of the pharmacokinetic trials in the farmed fish space, in addition to the broad husbandry animal applications, as presenting a significant opportunity to support the fish production and positively impact global food supply."

About Mountain Valley Md Holdings Inc.

Mountain Valley MD is building a world-class organization centred around the implementation, licensing and reselling of key technologies and formulations:

• Patented Quicksome oral formulation and delivery technologies;
• Patented Quicksol solubility formulation technology;
• Licensed product reseller of Agrarius, a novel agricultural plant signalling technology.

Consistent with its vision toward more life, Mountain Valley applies its owned and licensed technologies to its work for advanced delivery of molecules for human and animal husbandry applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety and more. Additionally, Mountain Valley's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

Mountain Valley's patented Quicksome technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

Mountain Valley's patented Quicksol technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

Mountain Valley's licensed Agrairus agricultural plant signalling technology could be capable of application to agricultural crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

We seek Safe Harbor.